ABBV Stock Chart & Fundamental Analysis

Interactive Chart

About AbbVie Inc.

Name

AbbVie Inc.

CEO

Robert A. Michael

Website

www.abbvie.com

Industry

Healthcare

Year Founded

2011

Employees

55,000

AbbVie Inc. is a biopharmaceutical company that researches, develops, and markets therapies across immunology, oncology, neuroscience, and other therapeutic areas. The company is known for both specialty medicines and a pipeline of investigational drugs designed to address chronic and complex diseases. Its research strategy emphasizes biologics, small molecules, and targeted therapies supported by clinical trials and global partnerships. With worldwide operations, AbbVie integrates advanced science with commercial scale to deliver healthcare solutions. Positioned within the healthcare sector, the company reflects the growing role of biotechnology in modern medicine.

Analyst Ratings

Consensus Recommendation

Buy5

Hold4

Sell12

Fundamentals & Financials

Revenue (TTM)

$59.6B

Net Income (TTM)

$2.3B

EPS (TTM)

$1.33

ROA (TTM)

1.78%

Current Ratio

0.72

Dividend Yield

0.1%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement (Quarterly)

Item	Q3 2025	Q2 2025	Q1 2025
Revenue	$15,776M	$15,423M	$13,343M
Cost of Sales	$5,304M	$4,346M	$4,002M
Gross Profit	$10,472M	$11,077M	$9,341M
Operating Income	$1,904M	$4,894M	$3,733M
Net Income	$186,000K	$938,000K	$1,286M
EPS	$0.1	$0.53	$0.72

Balance Sheet (Quarterly)

Financial Highlights (Quarterly)

Dividends History

Earnings Calendar (Quarterly)

Technical Indicators

AbbVie Inc.'s Technical Indicators Summary

AbbVie’s technical outlook remains neutral as of January 20, 2026, reflecting mixed signals across key indicators. Momentum measures like RSI near 37 and a negative MACD level suggest weakening price momentum, while the Commodity Channel Index points to selling pressure. The stock trades below most short- and medium-term moving averages, which signal bearishness, yet it remains above its 200-day averages, indicating some longer-term support. Volatility, measured by ATR, is moderate, and the ADX indicates a lack of strong trend momentum. Despite selling pressure on volume, oversold readings from stochastic and Williams %R hint at potential short-term buying interest. Overall, ABBV shows a balance between bearish trends and oversold conditions, resulting in a neutral technical stance.

Buy

5 signals

Neutral

4 signals

Sell

12 signals

Overall: Neutral19% Neutral signals

Indicator	Value	Signal	Explanation
RSI (14)	37.49	Neutral	RSI (37.49) is neutral.
Stochastic %K (14, 3, 3)	11.62	Buy	Stochastic (11.62) < 20, indicating oversold.
CCI (20)	-156.13	Sell	CCI (-156.13) < -100, indicating strong downward momentum.
WPR (14)	-97.97	Buy	Williams %R (-97.97) < -80, indicating oversold.
Momentum (10)	-14.96	Sell	Momentum (-14.96) is negative.
MFI	34.48	Neutral	MFI (34.48) is neutral.
MACD Level (12, 26)	-2.36	Sell	Confirmed downtrend: MACD (-2.36) is negative and below its signal line (-1.11).
Bollinger Bands	$214.53 - $235.48	Buy	Price ($214.35) is below the lower band ($214.53).
ATR (14)	$5.45 (2.54%)	Neutral	Moderate Volatility (2.54%).
ADX (14)	11.38	Neutral	Weak or consolidating trend (ADX < 25). ADX(11.38), +DI(19.43), -DI(24.38)
OBV	70,477,000	Sell	Bearish volume pressure: OBV is below its 20-day SMA. OBV(70,477,000), 20D-SMA-OBV(79,792,525)
Simple Moving Averages	$206.87 - $226.17(5 indicators)	Sell	The current price ($214.35) is below the short- to medium-term SMAs (10, 20, 50, and 100 periods) but remains above the long-term 200-period SMA, indicating short- to medium-term bearishness within an overall long-term bullish trend.
Exponential Moving Averages	$210.15 - $224.53(5 indicators)	Sell	The price is below the short- to medium-term EMAs (10, 20, 50, 100), indicating bearish momentum, but remains above the long-term 200-period EMA, suggesting underlying long-term support.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

The day concluded with ABBV keeping a mild 0.979% upside gap from yesterday, finishing at roughly 216.13. By the end of trading, the sector had posted a modest gain of 1.83%, offering a gentle tailwind. AbbVie's optimistic obesity-treatment expansion plans amid sector gains and recent conference optimism.

Price Change

from $214.04 close

+$2.1

Trading Volume

Above avg 7.9M

8.3M

vs S&P 500 Today

Outperforming Market

+0.91%

52-Week Position

Mid-range

64.3%